NEW YORK (Reuters Health)—In patients with active non-radiographic axial spondyloarthritis (nr-axSpA) who achieved remission while taking adalimumab, researchers saw fewer flares among those who continued taking the drug than among those who stopped taking it. “The results showed that continued therapy with adalimumab was associated with a higher rate of maintenance of remission compared with…
Help Patients Live Their Best Lives
September is national Rheumatic Disease Awareness Month. Encourage your patients to take the ACR’s pledge to live well with rheumatic disease, and help your community understand how these diseases affect your patients…
2019 Proposed Rule for MIPS Performance Year 3
The CMS has submitted its annual proposed rule, which continues the transition to a value-based model, for comment by stakeholders and the public for the 2019 MIPS performance year (Jan. 1–Dec. 31, 2019).
TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates
NEW YORK (Reuters Health)—Tumor necrosis factor (TNF) inhibitors do not appear to increase cancer-recurrence rates in patients with rheumatoid arthritis (RA), according to new findings from Sweden. TNF has both tumor-promoting and cancer-protective effects, so TNF inhibitors could conceivably affect the risk for cancer recurrence. However, few studies have reported the risk for cancer relapse…
Lyme Arthritis Treatment Protocols Critical as Lyme Disease Spreads
As Lyme disease and Lyme arthritis spread to new regions in North America, physicians may ned to become aware of their signs and symptoms. Allen C. Steere, MD, says “Lyme arthritis is more complicated to treat than other manifestations of the disease.” Here are some best practices for treating Lyme arthritis…
B Cell Receptor Clones May Predict RA Onset
Researchers have determined that dominant B cell receptor (BCR) clones in peripheral blood may predict the onset of clinical signs and symptoms of RA…
Osteoporosis Drugs Tied to Lower Fracture Risk & Health Costs
(Reuters Health)—Older women with osteoporosis who consistently take a bisphosphonate may have a lower risk of fractures and lower total health costs than their counterparts who stop taking these drugs, a U.S. study suggests. Researchers examined data on 294,369 women who were at least 66 years old, insured by Medicare and prescribed osteoporosis medicines for…
U.S. to Boost Drug Price Negotiation in Medicare Advantage Health Plans
(Reuters)—The Trump administration said on Tuesday it would give Medicare Advantage health plans for the elderly new tools to negotiate for lower prescription drug prices. The Centers for Medicare and Medicaid Services (CMS) said Medicare Advantage plans will be allowed to require that patients first try certain lower-cost drugs before moving to a more expensive…
AMA Opposes Merger of CVS & Aetna
WASHINGTON (Reuters)—the The American Medical Association, which represents U.S. physicians, urged the U.S. Justice Department on Wednesday to stop CVS Health Corp’s plan to buy insurance provider Aetna Inc, saying the deal could result in higher prices for prescription medicines. The AMA said that the $69 billion deal, announced in December, would lead to a…
Adalimumab Appears Safe for Treating Pediatric Patients with Autoimmune Disease
NEW YORK (Reuters Health)—Adalimumab appears to be safe for treating pediatric patients with polyarticular juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), psoriasis and Crohn’s disease (CD), according to data from company-sponsored clinical trials. Adalimumab is an anti-tumor necrosis factor monoclonal antibody with demonstrated efficacy in these conditions, but pediatric safety data remains limited. Dr. Gerd…
- « Previous Page
- 1
- …
- 155
- 156
- 157
- 158
- 159
- …
- 332
- Next Page »